Official source Data mirrored from Centers for Medicare & Medicaid Services Open Payments · General Payments · CMS publication 2026-06-30 View official record

Covered recipient · General Payments record

FIRAS B BADIN

Allopathic & Osteopathic Physicians Internal Medicine Hematology & Oncology

NPI
1588828693
CMS profile
343881
Location
LEXINGTON, KY

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

Saved items

Saved only in this browser. No account or alerts.

Filter and download payment records

General Payments · PY2024 · Entire year

$193,466.89

322 records · 0 disputed

Summary and payment records

  • CMS publication 2026-06-30
Read the payment records

“Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.”

— Centers for Medicare & Medicaid Services, Open Payments

A reported payment reflects a financial relationship a company disclosed. It does not indicate wrongdoing or a conflict of interest, and it says nothing about the quality of a provider's care.

These records are submitted to CMS and attested to by the reporting companies. CMS publishes them as reported; this site mirrors them without independent verification.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

How these totals are calculated
  • This total is the sum of the individual General Payments record amounts CMS published for the labeled program year(s); each record amount is used unmodified. The total itself is computed by this site. Nothing is estimated, weighted, or combined across categories.
  • General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
  • Methodology & Data — sourcing, labeling, and limitations.

Provider summaries generated . CMS updates this data on an annual cycle, and corrections or successful disputes made at CMS may not yet appear here. The official CMS record is authoritative for the current state. View the official CMS record ↗

By nature of payment

PY2024 · entire year · sorted by reported total

By paying entity

PY2024 · entire year · sorted by reported total

Paying entityAmountRecords
JAZZ PHARMACEUTICALS INC. $96,345.02 73
E.R. Squibb & Sons, L.L.C. $37,252.82 26
Lilly USA, LLC $16,671.62 18
PFIZER INC. $13,350.56 26
Merck Sharp & Dohme LLC $9,143.03 29
Amgen Inc. $3,938.85 7
ABBVIE INC. $3,807.70 12
Regeneron Healthcare Solutions, Inc. $2,713.01 10
BeiGene USA, Inc. $1,956.89 2
AstraZeneca Pharmaceuticals LP $1,941.07 12
Novartis Pharmaceuticals Corporation $1,749.10 16
Tempus AI, Inc $1,405.73 7
ARRAY BIOPHARMA INC $799.09 3
EMD Serono, Inc. $778.42 2
Genmab U.S., Inc. $238.72 12
Daiichi Sankyo Inc. $183.52 12
Janssen Biotech, Inc. $149.86 9
Janssen Scientific Affairs, LLC $113.70 1
Genentech, Inc. $86.96 1
Gilead Sciences, Inc. $64.31 3
Takeda Pharmaceuticals U.S.A., Inc. $63.57 3
Eisai Inc. $58.28 3
Astellas Pharma US Inc $53.22 3
Coherus Biosciences Inc. $52.33 3
TerSera Therapeutics LLC $48.57 2
ADC Therapeutics America, Inc. $44.53 2
Celgene Corporation $42.36 2
Stemline Therapeutics Inc. $39.59 2
PROGENICS PHARMACEUTICALS, INC. $39.11 2
Bayer Healthcare Pharmaceuticals Inc. $34.04 2
Kite Pharma, Inc. $33.94 2
Ipsen Biopharmaceuticals, Inc $29.98 2
Alexion Pharmaceuticals, Inc. $28.92 1
Siemens Medical Solutions USA, Inc. $26.45 1
SOBI, INC $25.71 1
GlaxoSmithKline, LLC. $23.36 1
Incyte Corporation $17.07 1
Kyowa Kirin, Inc. $16.60 1
SpringWorks Therapeutics, Inc. $15.52 1
Genentech USA, Inc. $15.32 1
Blueprint Medicines Corporation $14.44 1
Immunocore Limited $13.86 1
Apellis Pharmaceuticals, Inc. $13.73 1
SUN PHARMACEUTICAL INDUSTRIES INC. $13.33 1
TAIHO ONCOLOGY, INC. $13.08 1

Page 3 of 7; records 101–150 of 322 matching records. This page contains 50 records (maximum 50), not the full filtered export. Use the CSV download for all matching records.

IndustryPayments · General Payments

FIRAS B BADIN

NPI 1588828693 · CMS profile ID 343881

Allopathic & Osteopathic Physicians / Internal Medicine / Hematology & Oncology

LEXINGTON, KY

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

General Payments, PY2024; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types

Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00

Page 3 of 7; records 101–150 of 322 matching records. This page contains 50 records (maximum 50), not the full filtered export.

Filtered page: https://industrypayments.org/provider/npi-1588828693?year=2024&recipient=provider&page=3#records-h

CMS source: https://openpaymentsdata.cms.gov/dataset/e6b17c6a-2534-4207-a4a1-6746a14911ff

Cite these filtered records

The citation includes this program year, filters, data edition, and page of results.

Plain
FIRAS B BADIN, NPI 1588828693, CMS profile ID 343881. General Payments, PY2024; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 3 of 7; records 101–150 of 322 matching records. This page contains 50 records (maximum 50), not the full filtered export. IndustryPayments. https://industrypayments.org/provider/npi-1588828693?year=2024&recipient=provider&page=3#records-h. Source: https://openpaymentsdata.cms.gov/dataset/e6b17c6a-2534-4207-a4a1-6746a14911ff.
APA 7
IndustryPayments. (2026). FIRAS B BADIN, NPI 1588828693, CMS profile ID 343881. General Payments, PY2024; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 3 of 7; records 101–150 of 322 matching records. This page contains 50 records (maximum 50), not the full filtered export. [Filtered data set page]. https://industrypayments.org/provider/npi-1588828693?year=2024&recipient=provider&page=3#records-h. Source: https://openpaymentsdata.cms.gov/dataset/e6b17c6a-2534-4207-a4a1-6746a14911ff.
Bluebook
FIRAS B BADIN, NPI 1588828693, CMS profile ID 343881, IndustryPayments, General Payments, PY2024; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types (Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00). Page 3 of 7; records 101–150 of 322 matching records. This page contains 50 records (maximum 50), not the full filtered export. Source: https://openpaymentsdata.cms.gov/dataset/e6b17c6a-2534-4207-a4a1-6746a14911ff. https://industrypayments.org/provider/npi-1588828693?year=2024&recipient=provider&page=3#records-h.

Centers for Medicare & Medicaid Services, Open Payments

Citation formats are provided for reference; check the requirements of your publication.

Payment records · PY2024

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

General Payments · PY2024 · Physicians and non-physician practitioners · CMS publication 2026-06-30

322 matching records · $193,466.89 reported total · 0 disputed

Nature of payment: All payment types

Records imported here (UTC).

Link to these filtered records · CMS source dataset ↗

Download all 322 matching records (CSV)

CSV includes CMS record IDs, source and publication dates, the data edition, and a link to these filters. Formula-like text cells are prefixed with an apostrophe for spreadsheet safety.

Showing records 101–150 of 322.

Paying entityAmountDate Nature of paymentDispute statusPublication flagsPublished Record IDSource
Janssen Biotech, Inc. $14.6409/27/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1078651932 CMS
Incyte Corporation $17.0709/26/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1141276928 CMS
E.R. Squibb & Sons, L.L.C. $2,283.0009/25/2024 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1101217276 CMS
Astellas Pharma US Inc $17.5209/24/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1139395345 CMS
E.R. Squibb & Sons, L.L.C. $11.8809/23/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1101217272 CMS
JAZZ PHARMACEUTICALS INC. $4,340.0009/23/2024 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1150222228 CMS
PFIZER INC. $2.1209/23/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1130894911 CMS
PFIZER INC. $9.4409/23/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1130894915 CMS
Genmab U.S., Inc. $12.2609/21/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1126826600 CMS
Genmab U.S., Inc. $5.3009/20/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1126826594 CMS
Novartis Pharmaceuticals Corporation $8.3009/20/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1086739013 CMS
Novartis Pharmaceuticals Corporation $19.4509/20/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1086739015 CMS
PFIZER INC. $21.2709/20/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1131359366 CMS
Regeneron Healthcare Solutions, Inc. $659.0009/19/2024 Consulting Fee No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1114003201 CMS
Regeneron Healthcare Solutions, Inc. $659.0009/19/2024 Consulting Fee No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1114003203 CMS
Merck Sharp & Dohme LLC $16.4909/18/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1141709793 CMS
Lilly USA, LLC $20.1609/17/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1134976380 CMS
Alexion Pharmaceuticals, Inc. $28.9209/16/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1110531407 CMS
JAZZ PHARMACEUTICALS INC. $8.9509/16/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1150222258 CMS
JAZZ PHARMACEUTICALS INC. $16.1309/16/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1150222260 CMS
Janssen Biotech, Inc. $22.1309/16/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1078650019 CMS
E.R. Squibb & Sons, L.L.C. $665.9309/12/2024 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1101217290 CMS
E.R. Squibb & Sons, L.L.C. $467.1409/12/2024 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1101217294 CMS
E.R. Squibb & Sons, L.L.C. $243.0309/11/2024 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1101217274 CMS
E.R. Squibb & Sons, L.L.C. $583.5809/11/2024 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1101217278 CMS
E.R. Squibb & Sons, L.L.C. $179.5209/11/2024 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1101217280 CMS
Genmab U.S., Inc. $28.0009/11/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1126826596 CMS
ABBVIE INC. $21.7009/10/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1103261869 CMS
ABBVIE INC. $675.0009/09/2024 Consulting Fee No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1103131599 CMS
JAZZ PHARMACEUTICALS INC. $379.3509/07/2024 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1150222234 CMS
JAZZ PHARMACEUTICALS INC. $89.4009/07/2024 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1150222284 CMS
Regeneron Healthcare Solutions, Inc. $42.3309/07/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1114003199 CMS
Janssen Scientific Affairs, LLC $113.7009/06/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1078850820 CMS
Genentech USA, Inc. $15.3209/04/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1133011564 CMS
JAZZ PHARMACEUTICALS INC. $4,340.0009/03/2024 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1150222226 CMS
Kite Pharma, Inc. $15.0108/31/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1128612263 CMS
Daiichi Sankyo Inc. $15.3508/30/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1089395801 CMS
EMD Serono, Inc. $13.4208/30/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1120262088 CMS
PFIZER INC. $720.0008/30/2024 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1132058098 CMS
Daiichi Sankyo Inc. $16.5908/28/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1089395799 CMS
E.R. Squibb & Sons, L.L.C. $2.2708/28/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1101217266 CMS
JAZZ PHARMACEUTICALS INC. $82.6808/28/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1150222282 CMS
ABBVIE INC. $4.9108/27/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1103261867 CMS
ABBVIE INC. $1.7208/26/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1103261865 CMS
Janssen Biotech, Inc. $20.6608/26/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1078651676 CMS
ARRAY BIOPHARMA INC $19.4608/23/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1131900847 CMS
Daiichi Sankyo Inc. $20.1108/21/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1089395797 CMS
JAZZ PHARMACEUTICALS INC. $73.0408/21/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1150222280 CMS
Merck Sharp & Dohme LLC $13.3708/21/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1141709937 CMS
AstraZeneca Pharmaceuticals LP $31.2208/19/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1110543143 CMS

By program year

All program years on this page · sorted by year

Program yearAmountRecords
PY2019 $270,162.62 415
PY2020 $127,731.79 160
PY2021 $310,946.34 285
PY2022 $221,105.54 282
PY2023 $255,982.08 279
PY2024 $193,466.89 322
PY2025 $177,717.90 311

Source & provenance

Dataset
CMS Open Payments — General Payments
Publisher of source data
Centers for Medicare & Medicaid Services
CMS publication date
2026-06-30
Program years on this page
2019, 2020, 2021, 2022, 2023, 2024, 2025
Source files and profile matching
Generated from
OP_DTL_GNRL_PGYR2025_P06302026_06032026.csv

One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.

Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.

Research Payments

One row per program year and role, newest year first · amounts for the two roles are never added together

Program yearRoleAmountRecords
PY2025 Recipient $4,730.94 11
PY2025 Principal investigator $611,999.68 149
PY2024 Principal investigator $536,455.75 128
PY2023 Principal investigator $951,304.72 73
PY2022 Principal investigator $948,134.72 82
PY2021 Principal investigator $722,869.16 116
PY2020 Principal investigator $785,041.40 102
PY2019 Principal investigator $589,534.05 17

Research Payments are a separate CMS dataset, shown here separately and never added to General Payments. A research payment is often made to an institution, with this provider named as a principal investigator; each record states which role applies.

“If you are a physician who served as a principal investigator on a research study, you may see the payments associated with that research study listed under your name. This does not necessarily mean the payments are attributed to you. The dollar amount of the record corresponds to the total payment; the amounts are not attributed to each individual on the record.”

— Centers for Medicare & Medicaid Services, Open Payments Frequently Asked Questions, FAQ #12224

Research Payments records · PY2025

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

160 records in PY2025

Research Payments records (CSV)

RolePaying entityAmount DateRecipientStudy Dispute statusPublishedRecord ID
Principal investigator 1 Merck Sharp & Dohme LLC $8,497.86 12/31/2025 Covered Recipient Teaching Hospital
Baptist Health Lexington
A Randomized, Phase 3, Open-label Study to Investigate the Pharmacokinetics and Safety of Subcutaneous Pembrolizumab versus Intravenous Pembrolizumab, Administered with Platinum Doublet Chemotherapy, in the First-Line Treatment of Participants with Metast No dispute reported 06/30/2026 1232927735
Principal investigator 1 Mirati Therapeutics, Inc. $58,962.30 12/26/2025 Covered Recipient Teaching Hospital
Baptist Health Lexington
A Phase 2 Trial of MRTX849 Monotherapy and in Combination With Pembrolizumab in Patients With Advanced Non-Small Cell Lung Cancer With KRAS G12C Mutation No dispute reported 06/30/2026 1236530148
Principal investigator 1 Daiichi Sankyo Inc. $3,202.00 12/15/2025 Covered Recipient Teaching Hospital
Baptist Health Lexington
DS7300-188 No dispute reported 06/30/2026 1223344191
Principal investigator 1 Daiichi Sankyo Inc. $3,202.00 12/15/2025 Covered Recipient Teaching Hospital
Baptist Health Lexington
DS7300-188 No dispute reported 06/30/2026 1223344195
Principal investigator 1 E.R. Squibb & Sons, L.L.C. $24,945.00 12/15/2025 Covered Recipient Teaching Hospital
Baptist Health Lexington
A Randomized Phase 2/3 Study of BMS-986504 in Combination with Pembrolizumab and Chemotherapy Versus Placebo Plus Pembrolizumab and Chemotherapy in First-line Metastatic Non-small Cell Lung Cancer Participants with Homozygous MTAP Deletion No dispute reported 06/30/2026 1236001749
Principal investigator 1 ABBVIE INC. $3,913.70 12/04/2025 Covered Recipient Teaching Hospital
BAPTIST HEALTH LEXINGTON
Study to Evaluate Adverse Events Optimal Dose and Change in Disease Activity With Livmoniplimab in Combination With Budigalimab Plus Chemotherapy Versus IV Infused Pembrolizumab Plus Chemotherapy in Adult Participants With Untreated Metastatic Non-Squamous Non-Small Cell Lung Cancer (NSCLC) No dispute reported 06/30/2026 1202406087
Principal investigator 1 BeOne Medicines Ltd. $1,000.00 11/26/2025 Covered Recipient Teaching Hospital
Baptist Health Lexington
A Randomized, Controlled, Open-label, Global Phase 3 Study Comparing the Efficacy of the Anti-PD-1 Antibody Tislelizumab (BGB-A317) Versus Chemotherapy as Second Line Treatment in Patients With Advanced Unresectable/Metastatic Esophageal Squamous Cell Carcinoma No dispute reported 06/30/2026 1190329261
Principal investigator 1 BeOne Medicines Ltd. $1,500.00 11/26/2025 Covered Recipient Teaching Hospital
Baptist Health Lexington
A Randomized, Controlled, Open-label, Global Phase 3 Study Comparing the Efficacy of the Anti-PD-1 Antibody Tislelizumab (BGB-A317) Versus Chemotherapy as Second Line Treatment in Patients With Advanced Unresectable/Metastatic Esophageal Squamous Cell Carcinoma No dispute reported 06/30/2026 1190329291
Principal investigator 1 BeOne Medicines Ltd. $1,178.00 11/26/2025 Covered Recipient Teaching Hospital
Baptist Health Lexington
A Randomized, Controlled, Open-label, Global Phase 3 Study Comparing the Efficacy of the Anti-PD-1 Antibody Tislelizumab (BGB-A317) Versus Chemotherapy as Second Line Treatment in Patients With Advanced Unresectable/Metastatic Esophageal Squamous Cell Carcinoma No dispute reported 06/30/2026 1190334517
Principal investigator 1 Daiichi Sankyo Inc. $577.00 11/19/2025 Covered Recipient Teaching Hospital
Baptist Health Lexington
DS7300-188 No dispute reported 06/30/2026 1223344193
Principal investigator 1 Genmab A/S $1,000.00 11/17/2025 Non-covered Recipient Entity
BAPTIST HEALTHCARE SYSTEMS INC.
A Prospective, Open-Label, Randomized, Phase 3 Trial of Acasunlimab (GEN1046) in Combination With Pembrolizumab Versus Docetaxel in Subjects With PD-L1 Positive Metastatic Non-Small Cell Lung Cancer After Treatment With a PD-1/PD-L1 Inhibitor and Platinum-Containing Chemotherapy (ABBIL1TY NSCLC-06) No dispute reported 06/30/2026 1235927667
Principal investigator 1 Genmab A/S $1,139.00 11/17/2025 Non-covered Recipient Entity
BAPTIST HEALTHCARE SYSTEMS INC.
A Prospective, Open-Label, Randomized, Phase 3 Trial of Acasunlimab (GEN1046) in Combination With Pembrolizumab Versus Docetaxel in Subjects With PD-L1 Positive Metastatic Non-Small Cell Lung Cancer After Treatment With a PD-1/PD-L1 Inhibitor and Platinum-Containing Chemotherapy (ABBIL1TY NSCLC-06) No dispute reported 06/30/2026 1235927671
Principal investigator 1 Genmab A/S $14,500.00 11/17/2025 Non-covered Recipient Entity
BAPTIST HEALTHCARE SYSTEMS INC.
A Prospective, Open-Label, Randomized, Phase 3 Trial of Acasunlimab (GEN1046) in Combination With Pembrolizumab Versus Docetaxel in Subjects With PD-L1 Positive Metastatic Non-Small Cell Lung Cancer After Treatment With a PD-1/PD-L1 Inhibitor and Platinum-Containing Chemotherapy (ABBIL1TY NSCLC-06) No dispute reported 06/30/2026 1235927675
Principal investigator 1 Genmab A/S $2,036.00 11/17/2025 Non-covered Recipient Entity
BAPTIST HEALTHCARE SYSTEMS INC.
A Prospective, Open-Label, Randomized, Phase 3 Trial of Acasunlimab (GEN1046) in Combination With Pembrolizumab Versus Docetaxel in Subjects With PD-L1 Positive Metastatic Non-Small Cell Lung Cancer After Treatment With a PD-1/PD-L1 Inhibitor and Platinum-Containing Chemotherapy (ABBIL1TY NSCLC-06) No dispute reported 06/30/2026 1235927679
Principal investigator 1 Genmab A/S $2,000.00 11/17/2025 Non-covered Recipient Entity
BAPTIST HEALTHCARE SYSTEMS INC.
A Prospective, Open-Label, Randomized, Phase 3 Trial of Acasunlimab (GEN1046) in Combination With Pembrolizumab Versus Docetaxel in Subjects With PD-L1 Positive Metastatic Non-Small Cell Lung Cancer After Treatment With a PD-1/PD-L1 Inhibitor and Platinum-Containing Chemotherapy (ABBIL1TY NSCLC-06) No dispute reported 06/30/2026 1235927683
Principal investigator 1 Daiichi Sankyo Inc. $62.00 11/12/2025 Covered Recipient Teaching Hospital
Baptist Health Lexington
DS7300-188 No dispute reported 06/30/2026 1223344197
Principal investigator 1 Daiichi Sankyo Inc. $46.50 11/12/2025 Covered Recipient Teaching Hospital
Baptist Health Lexington
DS7300-188 No dispute reported 06/30/2026 1223344199
Principal investigator 1 Daiichi Sankyo Inc. $54.75 11/12/2025 Covered Recipient Teaching Hospital
Baptist Health Lexington
DS7300-188 No dispute reported 06/30/2026 1223344217
Principal investigator 1 Daiichi Sankyo Inc. $46.50 11/12/2025 Covered Recipient Teaching Hospital
Baptist Health Lexington
DS7300-188 No dispute reported 06/30/2026 1223344219
Principal investigator 1 Daiichi Sankyo Inc. $62.55 11/12/2025 Covered Recipient Teaching Hospital
Baptist Health Lexington
DS7300-188 No dispute reported 06/30/2026 1223344221
Principal investigator 1 ABBVIE INC. $7,381.78 11/05/2025 Covered Recipient Teaching Hospital
BAPTIST HEALTH LEXINGTON
Study to Evaluate Adverse Events Optimal Dose and Change in Disease Activity With Livmoniplimab in Combination With Budigalimab Plus Chemotherapy Versus IV Infused Pembrolizumab Plus Chemotherapy in Adult Participants With Untreated Metastatic Non-Squamous Non-Small Cell Lung Cancer (NSCLC) No dispute reported 06/30/2026 1202406079
Principal investigator 1 Daiichi Sankyo Inc. $6,465.00 11/03/2025 Covered Recipient Teaching Hospital
Baptist Health Lexington
DS7300-188 No dispute reported 06/30/2026 1223344201
Principal investigator 1 Daiichi Sankyo Inc. $2,951.00 11/03/2025 Covered Recipient Teaching Hospital
Baptist Health Lexington
DS7300-188 No dispute reported 06/30/2026 1223344203
Principal investigator 1 Daiichi Sankyo Inc. $3,202.00 11/03/2025 Covered Recipient Teaching Hospital
Baptist Health Lexington
DS7300-188 No dispute reported 06/30/2026 1223344205
Principal investigator 1 Daiichi Sankyo Inc. $3,756.00 11/03/2025 Covered Recipient Teaching Hospital
Baptist Health Lexington
DS7300-188 No dispute reported 06/30/2026 1223344207
Principal investigator 1 Daiichi Sankyo Inc. $3,202.00 11/03/2025 Covered Recipient Teaching Hospital
Baptist Health Lexington
DS7300-188 No dispute reported 06/30/2026 1223344209
Principal investigator 1 Daiichi Sankyo Inc. $2,951.00 11/03/2025 Covered Recipient Teaching Hospital
Baptist Health Lexington
DS7300-188 No dispute reported 06/30/2026 1223344211
Principal investigator 1 Daiichi Sankyo Inc. $3,202.00 11/03/2025 Covered Recipient Teaching Hospital
Baptist Health Lexington
DS7300-188 No dispute reported 06/30/2026 1223344213
Principal investigator 1 Daiichi Sankyo Inc. $900.00 11/03/2025 Covered Recipient Teaching Hospital
Baptist Health Lexington
DS7300-188 No dispute reported 06/30/2026 1223344215
Principal investigator 1 E.R. Squibb & Sons, L.L.C. $2,082.84 10/27/2025 Covered Recipient Teaching Hospital
Baptist Health Lexington
A Randomized Phase 2/3 Study of BMS-986504 in Combination with Pembrolizumab and Chemotherapy Versus Placebo Plus Pembrolizumab and Chemotherapy in First-line Metastatic Non-small Cell Lung Cancer Participants with Homozygous MTAP Deletion No dispute reported 06/30/2026 1236001751
Principal investigator 1 ABBVIE INC. $20,468.71 10/09/2025 Covered Recipient Teaching Hospital
BAPTIST HEALTH LEXINGTON
Study to Evaluate Adverse Events Optimal Dose and Change in Disease Activity With Livmoniplimab in Combination With Budigalimab Plus Chemotherapy Versus IV Infused Pembrolizumab Plus Chemotherapy in Adult Participants With Untreated Metastatic Non-Squamous Non-Small Cell Lung Cancer (NSCLC) No dispute reported 06/30/2026 1202406076
Principal investigator 1 Daiichi Sankyo Inc. $1,690.00 09/17/2025 Covered Recipient Teaching Hospital
Baptist Health Lexington
DS7300-188 No dispute reported 06/30/2026 1223344083
Principal investigator 1 Daiichi Sankyo Inc. $2,507.00 09/17/2025 Covered Recipient Teaching Hospital
Baptist Health Lexington
DS7300-188 No dispute reported 06/30/2026 1223344085
Principal investigator 1 Daiichi Sankyo Inc. $3,202.00 09/17/2025 Covered Recipient Teaching Hospital
Baptist Health Lexington
DS7300-188 No dispute reported 06/30/2026 1223344087
Principal investigator 1 Daiichi Sankyo Inc. $3,668.00 09/17/2025 Covered Recipient Teaching Hospital
Baptist Health Lexington
DS7300-188 No dispute reported 06/30/2026 1223344089
Principal investigator 1 Daiichi Sankyo Inc. $2,597.00 09/17/2025 Covered Recipient Teaching Hospital
Baptist Health Lexington
DS7300-188 No dispute reported 06/30/2026 1223344091
Principal investigator 1 Daiichi Sankyo Inc. $2,918.00 09/17/2025 Covered Recipient Teaching Hospital
Baptist Health Lexington
DS7300-188 No dispute reported 06/30/2026 1223344093
Principal investigator 1 Daiichi Sankyo Inc. $6,465.00 09/17/2025 Covered Recipient Teaching Hospital
Baptist Health Lexington
DS7300-188 No dispute reported 06/30/2026 1223344109
Principal investigator 1 Daiichi Sankyo Inc. $1,477.00 09/17/2025 Covered Recipient Teaching Hospital
Baptist Health Lexington
DS7300-188 No dispute reported 06/30/2026 1223344111
Principal investigator 1 Daiichi Sankyo Inc. $1,477.00 09/17/2025 Covered Recipient Teaching Hospital
Baptist Health Lexington
DS7300-188 No dispute reported 06/30/2026 1223344113
Principal investigator 1 Daiichi Sankyo Inc. $1,477.00 09/17/2025 Covered Recipient Teaching Hospital
Baptist Health Lexington
DS7300-188 No dispute reported 06/30/2026 1223344115
Principal investigator 1 Daiichi Sankyo Inc. $3,595.00 09/17/2025 Covered Recipient Teaching Hospital
Baptist Health Lexington
DS7300-188 No dispute reported 06/30/2026 1223344117
Principal investigator 1 Daiichi Sankyo Inc. $3,756.00 09/17/2025 Covered Recipient Teaching Hospital
Baptist Health Lexington
DS7300-188 No dispute reported 06/30/2026 1223344119
Principal investigator 1 Daiichi Sankyo Inc. $2,597.00 09/17/2025 Covered Recipient Teaching Hospital
Baptist Health Lexington
DS7300-188 No dispute reported 06/30/2026 1223344121
Principal investigator 1 Daiichi Sankyo Inc. $2,507.00 09/17/2025 Covered Recipient Teaching Hospital
Baptist Health Lexington
DS7300-188 No dispute reported 06/30/2026 1223344123
Principal investigator 1 Daiichi Sankyo Inc. $2,597.00 09/17/2025 Covered Recipient Teaching Hospital
Baptist Health Lexington
DS7300-188 No dispute reported 06/30/2026 1223344125
Principal investigator 1 Daiichi Sankyo Inc. $4,894.00 09/17/2025 Covered Recipient Teaching Hospital
Baptist Health Lexington
DS7300-188 No dispute reported 06/30/2026 1223344127
Principal investigator 1 Daiichi Sankyo Inc. $3,202.00 09/17/2025 Covered Recipient Teaching Hospital
Baptist Health Lexington
DS7300-188 No dispute reported 06/30/2026 1223344129
Principal investigator 1 Daiichi Sankyo Inc. $2,918.00 09/17/2025 Covered Recipient Teaching Hospital
Baptist Health Lexington
DS7300-188 No dispute reported 06/30/2026 1223344131
Principal investigator 1 Daiichi Sankyo Inc. $3,704.00 09/17/2025 Covered Recipient Teaching Hospital
Baptist Health Lexington
DS7300-188 No dispute reported 06/30/2026 1223344177
Principal investigator 1 Daiichi Sankyo Inc. $6,465.00 09/17/2025 Covered Recipient Teaching Hospital
Baptist Health Lexington
DS7300-188 No dispute reported 06/30/2026 1223344181
Principal investigator 1 Daiichi Sankyo Inc. $3,202.00 09/17/2025 Covered Recipient Teaching Hospital
Baptist Health Lexington
DS7300-188 No dispute reported 06/30/2026 1223344187
Principal investigator 1 Daiichi Sankyo Inc. $3,202.00 09/17/2025 Covered Recipient Teaching Hospital
Baptist Health Lexington
DS7300-188 No dispute reported 06/30/2026 1223344189
Principal investigator 1 Daiichi Sankyo Inc. $2,000.00 09/12/2025 Covered Recipient Teaching Hospital
Baptist Health Lexington
DS7300-188 No dispute reported 06/30/2026 1223344095
Principal investigator 1 Daiichi Sankyo Inc. $750.00 09/12/2025 Covered Recipient Teaching Hospital
Baptist Health Lexington
DS7300-188 No dispute reported 06/30/2026 1223344097
Principal investigator 1 Daiichi Sankyo Inc. $780.00 09/12/2025 Covered Recipient Teaching Hospital
Baptist Health Lexington
DS7300-188 No dispute reported 06/30/2026 1223344099
Principal investigator 1 Daiichi Sankyo Inc. $14,000.00 09/12/2025 Covered Recipient Teaching Hospital
Baptist Health Lexington
DS7300-188 No dispute reported 06/30/2026 1223344101
Principal investigator 1 Daiichi Sankyo Inc. $43.00 09/12/2025 Covered Recipient Teaching Hospital
Baptist Health Lexington
DS7300-188 No dispute reported 06/30/2026 1223344103
Principal investigator 1 Daiichi Sankyo Inc. $4,000.00 09/12/2025 Covered Recipient Teaching Hospital
Baptist Health Lexington
DS7300-188 No dispute reported 06/30/2026 1223344105
Principal investigator 1 Daiichi Sankyo Inc. $94.00 09/12/2025 Covered Recipient Teaching Hospital
Baptist Health Lexington
DS7300-188 No dispute reported 06/30/2026 1223344107
Principal investigator 1 ABBVIE INC. $12,690.33 09/04/2025 Covered Recipient Teaching Hospital
BAPTIST HEALTH LEXINGTON
Study to Evaluate Adverse Events Optimal Dose and Change in Disease Activity With Livmoniplimab in Combination With Budigalimab Plus Chemotherapy Versus IV Infused Pembrolizumab Plus Chemotherapy in Adult Participants With Untreated Metastatic Non-Squamous Non-Small Cell Lung Cancer (NSCLC) No dispute reported 06/30/2026 1202406073
Principal investigator 1 GlaxoSmithKline, LLC. $700.00 08/28/2025 Non-covered Recipient Entity
BAPTIST HEALTHCARE SYSTEM INC
A RANDOMIZED, MULTICENTER, DOUBLE-BLIND, PHASE 3 STUDY TO INVESTIGATE No dispute reported 06/30/2026 1192098688
Principal investigator 1 GlaxoSmithKline, LLC. $2,380.00 08/28/2025 Non-covered Recipient Entity
BAPTIST HEALTHCARE SYSTEM INC
A RANDOMIZED, MULTICENTER, DOUBLE-BLIND, PHASE 3 STUDY TO INVESTIGATE No dispute reported 06/30/2026 1192098698
Principal investigator 1 GlaxoSmithKline, LLC. $905.80 08/28/2025 Non-covered Recipient Entity
BAPTIST HEALTHCARE SYSTEM INC
A RANDOMIZED, MULTICENTER, DOUBLE-BLIND, PHASE 3 STUDY TO INVESTIGATE No dispute reported 06/30/2026 1192150308
Principal investigator 1 GlaxoSmithKline, LLC. $686.00 08/28/2025 Non-covered Recipient Entity
BAPTIST HEALTHCARE SYSTEM INC
A RANDOMIZED, MULTICENTER, DOUBLE-BLIND, PHASE 3 STUDY TO INVESTIGATE No dispute reported 06/30/2026 1192150317
Principal investigator 1 GlaxoSmithKline, LLC. $4,900.00 08/28/2025 Non-covered Recipient Entity
BAPTIST HEALTHCARE SYSTEM INC
A RANDOMIZED, MULTICENTER, DOUBLE-BLIND, PHASE 3 STUDY TO INVESTIGATE No dispute reported 06/30/2026 1192150322
Principal investigator 1 GlaxoSmithKline, LLC. $35.00 08/28/2025 Non-covered Recipient Entity
BAPTIST HEALTHCARE SYSTEM INC
A RANDOMIZED, MULTICENTER, DOUBLE-BLIND, PHASE 3 STUDY TO INVESTIGATE No dispute reported 06/30/2026 1192150326
Principal investigator 1 GlaxoSmithKline, LLC. $1,820.00 08/28/2025 Non-covered Recipient Entity
BAPTIST HEALTHCARE SYSTEM INC
A RANDOMIZED, MULTICENTER, DOUBLE-BLIND, PHASE 3 STUDY TO INVESTIGATE No dispute reported 06/30/2026 1192150339
Principal investigator 1 GlaxoSmithKline, LLC. $2,800.00 08/28/2025 Non-covered Recipient Entity
BAPTIST HEALTHCARE SYSTEM INC
A RANDOMIZED, MULTICENTER, DOUBLE-BLIND, PHASE 3 STUDY TO INVESTIGATE No dispute reported 06/30/2026 1192154225
Principal investigator 1 GlaxoSmithKline, LLC. $385.00 08/28/2025 Non-covered Recipient Entity
BAPTIST HEALTHCARE SYSTEM INC
A RANDOMIZED, MULTICENTER, DOUBLE-BLIND, PHASE 3 STUDY TO INVESTIGATE No dispute reported 06/30/2026 1192154232
Principal investigator 1 GlaxoSmithKline, LLC. $453.60 08/28/2025 Non-covered Recipient Entity
BAPTIST HEALTHCARE SYSTEM INC
A RANDOMIZED, MULTICENTER, DOUBLE-BLIND, PHASE 3 STUDY TO INVESTIGATE No dispute reported 06/30/2026 1192154243
Principal investigator 1 GlaxoSmithKline, LLC. $5,362.00 08/28/2025 Non-covered Recipient Entity
BAPTIST HEALTHCARE SYSTEM INC
A RANDOMIZED, MULTICENTER, DOUBLE-BLIND, PHASE 3 STUDY TO INVESTIGATE No dispute reported 06/30/2026 1192154247
Principal investigator 1 Genentech, Inc. $27,000.00 08/19/2025 Covered Recipient Teaching Hospital
Baptist Health Lexington
A PHASE III, RANDOMIZED, OPEN-LABEL, MULTICENTER STUDY EVALUATING THE EFFICACY AND SAFETY OF DIVARAS No dispute reported 06/30/2026 1211541039
Principal investigator 1 GlaxoSmithKline, LLC. $3,795.40 08/12/2025 Non-covered Recipient Entity
BAPTIST HEALTHCARE SYSTEM INC
A RANDOMIZED, MULTICENTER, DOUBLE-BLIND, PHASE 3 STUDY TO INVESTIGATE No dispute reported 06/30/2026 1192098693
Principal investigator 1 Daiichi Sankyo Inc. $46.50 08/11/2025 Covered Recipient Teaching Hospital
Baptist Health Lexington
DS7300-188 No dispute reported 06/30/2026 1223344081
Principal investigator 1 Daiichi Sankyo Inc. $46.50 08/11/2025 Covered Recipient Teaching Hospital
Baptist Health Lexington
DS7300-188 No dispute reported 06/30/2026 1223344133
Principal investigator 1 Daiichi Sankyo Inc. $13.20 08/11/2025 Covered Recipient Teaching Hospital
Baptist Health Lexington
DS7300-188 No dispute reported 06/30/2026 1223344135
Principal investigator 1 Daiichi Sankyo Inc. $200.75 08/11/2025 Covered Recipient Teaching Hospital
Baptist Health Lexington
DS7300-188 No dispute reported 06/30/2026 1223344137
Principal investigator 1 Daiichi Sankyo Inc. $62.00 08/11/2025 Covered Recipient Teaching Hospital
Baptist Health Lexington
DS7300-188 No dispute reported 06/30/2026 1223344139
Principal investigator 1 Daiichi Sankyo Inc. $46.50 08/11/2025 Covered Recipient Teaching Hospital
Baptist Health Lexington
DS7300-188 No dispute reported 06/30/2026 1223344141
Principal investigator 1 Daiichi Sankyo Inc. $46.50 08/11/2025 Covered Recipient Teaching Hospital
Baptist Health Lexington
DS7300-188 No dispute reported 06/30/2026 1223344143
Principal investigator 1 Daiichi Sankyo Inc. $62.00 08/11/2025 Covered Recipient Teaching Hospital
Baptist Health Lexington
DS7300-188 No dispute reported 06/30/2026 1223344145
Principal investigator 1 Daiichi Sankyo Inc. $46.50 08/11/2025 Covered Recipient Teaching Hospital
Baptist Health Lexington
DS7300-188 No dispute reported 06/30/2026 1223344147
Principal investigator 1 Daiichi Sankyo Inc. $62.00 08/11/2025 Covered Recipient Teaching Hospital
Baptist Health Lexington
DS7300-188 No dispute reported 06/30/2026 1223344149
Principal investigator 1 Daiichi Sankyo Inc. $46.50 08/11/2025 Covered Recipient Teaching Hospital
Baptist Health Lexington
DS7300-188 No dispute reported 06/30/2026 1223344151
Principal investigator 1 Daiichi Sankyo Inc. $46.50 08/11/2025 Covered Recipient Teaching Hospital
Baptist Health Lexington
DS7300-188 No dispute reported 06/30/2026 1223344153
Principal investigator 1 Daiichi Sankyo Inc. $46.50 08/11/2025 Covered Recipient Teaching Hospital
Baptist Health Lexington
DS7300-188 No dispute reported 06/30/2026 1223344155
Principal investigator 1 Daiichi Sankyo Inc. $46.50 08/11/2025 Covered Recipient Teaching Hospital
Baptist Health Lexington
DS7300-188 No dispute reported 06/30/2026 1223344157
Principal investigator 1 Daiichi Sankyo Inc. $46.50 08/11/2025 Covered Recipient Teaching Hospital
Baptist Health Lexington
DS7300-188 No dispute reported 06/30/2026 1223344159
Principal investigator 1 Daiichi Sankyo Inc. $46.50 08/11/2025 Covered Recipient Teaching Hospital
Baptist Health Lexington
DS7300-188 No dispute reported 06/30/2026 1223344161
Principal investigator 1 Daiichi Sankyo Inc. $46.50 08/11/2025 Covered Recipient Teaching Hospital
Baptist Health Lexington
DS7300-188 No dispute reported 06/30/2026 1223344163
Principal investigator 1 Daiichi Sankyo Inc. $112.05 08/11/2025 Covered Recipient Teaching Hospital
Baptist Health Lexington
DS7300-188 No dispute reported 06/30/2026 1223344165
Principal investigator 1 Daiichi Sankyo Inc. $62.55 08/11/2025 Covered Recipient Teaching Hospital
Baptist Health Lexington
DS7300-188 No dispute reported 06/30/2026 1223344167
Principal investigator 1 Daiichi Sankyo Inc. $62.00 08/11/2025 Covered Recipient Teaching Hospital
Baptist Health Lexington
DS7300-188 No dispute reported 06/30/2026 1223344169
Principal investigator 1 Daiichi Sankyo Inc. $46.50 08/11/2025 Covered Recipient Teaching Hospital
Baptist Health Lexington
DS7300-188 No dispute reported 06/30/2026 1223344171
Principal investigator 1 Daiichi Sankyo Inc. $46.50 08/11/2025 Covered Recipient Teaching Hospital
Baptist Health Lexington
DS7300-188 No dispute reported 06/30/2026 1223344173
Principal investigator 1 Daiichi Sankyo Inc. $104.25 08/11/2025 Covered Recipient Teaching Hospital
Baptist Health Lexington
DS7300-188 No dispute reported 06/30/2026 1223344175
Principal investigator 1 Daiichi Sankyo Inc. $57.75 08/11/2025 Covered Recipient Teaching Hospital
Baptist Health Lexington
DS7300-188 No dispute reported 06/30/2026 1223344179
Principal investigator 1 Daiichi Sankyo Inc. $46.50 08/11/2025 Covered Recipient Teaching Hospital
Baptist Health Lexington
DS7300-188 No dispute reported 06/30/2026 1223344183
Principal investigator 1 Daiichi Sankyo Inc. $46.50 08/11/2025 Covered Recipient Teaching Hospital
Baptist Health Lexington
DS7300-188 No dispute reported 06/30/2026 1223344185
Principal investigator 1 ABBVIE INC. $9,197.40 07/22/2025 Covered Recipient Teaching Hospital
BAPTIST HEALTH LEXINGTON
Study to Evaluate Adverse Events Optimal Dose and Change in Disease Activity With Livmoniplimab in Combination With Budigalimab Plus Chemotherapy Versus IV Infused Pembrolizumab Plus Chemotherapy in Adult Participants With Untreated Metastatic Non-Squamous Non-Small Cell Lung Cancer (NSCLC) No dispute reported 06/30/2026 1202406069
Principal investigator 1 ABBVIE INC. $874.30 07/02/2025 Covered Recipient Teaching Hospital
BAPTIST HEALTH LEXINGTON
Study to Evaluate Adverse Events Optimal Dose and Change in Disease Activity With Livmoniplimab in Combination With Budigalimab Plus Chemotherapy Versus IV Infused Pembrolizumab Plus Chemotherapy in Adult Participants With Untreated Metastatic Non-Squamous Non-Small Cell Lung Cancer (NSCLC) No dispute reported 06/30/2026 1202406066
Principal investigator 1 GlaxoSmithKline, LLC. $1,092.00 06/20/2025 Non-covered Recipient Entity
BAPTIST HEALTHCARE SYSTEM INC
A RANDOMIZED, MULTICENTER, DOUBLE-BLIND, PHASE 3 STUDY TO INVESTIGATE No dispute reported 06/30/2026 1192150335
Principal investigator 1 GlaxoSmithKline, LLC. $385.00 06/20/2025 Non-covered Recipient Entity
BAPTIST HEALTHCARE SYSTEM INC
A RANDOMIZED, MULTICENTER, DOUBLE-BLIND, PHASE 3 STUDY TO INVESTIGATE No dispute reported 06/30/2026 1192154228
Principal investigator 1 GlaxoSmithKline, LLC. $5,073.60 06/11/2025 Non-covered Recipient Entity
BAPTIST HEALTHCARE SYSTEM INC
A RANDOMIZED, MULTICENTER, DOUBLE-BLIND, PHASE 3 STUDY TO INVESTIGATE No dispute reported 06/30/2026 1192150313
Principal investigator 1 GlaxoSmithKline, LLC. $10,689.00 06/11/2025 Non-covered Recipient Entity
BAPTIST HEALTHCARE SYSTEM INC
A RANDOMIZED, MULTICENTER, DOUBLE-BLIND, PHASE 3 STUDY TO INVESTIGATE No dispute reported 06/30/2026 1192154237
Principal investigator 1 JAZZ PHARMACEUTICALS INC. $2,000.00 06/05/2025 Covered Recipient Teaching Hospital
Baptist Health Lexington
EMERGE 402: Phase IV Observational Study to Collect Safety and Outcome Data in Real-World Setting in Adult Patients With Extensive Stage Small Cell Lung Cancer (SCLC) Receiving Zepzelca No dispute reported 06/30/2026 1233734864
Principal investigator 1 JAZZ PHARMACEUTICALS INC. $376.00 06/05/2025 Covered Recipient Teaching Hospital
Baptist Health Lexington
EMERGE 402: Phase IV Observational Study to Collect Safety and Outcome Data in Real-World Setting in Adult Patients With Extensive Stage Small Cell Lung Cancer (SCLC) Receiving Zepzelca No dispute reported 06/30/2026 1233734866
Principal investigator 1 AstraZeneca Pharmaceuticals LP $27,066.28 05/16/2025 Covered Recipient Teaching Hospital
Baptist Health Lexington
A Phase III, Randomised, Open-label, Global Study of Adjuvant Datopotamab Deruxtecan (Dato-DXd) in Combination With Rilvegostomig or Rilvegostomig Monotherapy Versus Standard of Care in Participants With Stage I Adenocarcinoma Non-small Cell Lung Cancer who are ctDNA-positive or Have High-risk Pathological Features, Following Complete Tumour Resection (TROPION Lung12) No dispute reported 06/30/2026 1185545449
Principal investigator 1 BeiGene, Ltd. $2,450.00 05/14/2025 Covered Recipient Teaching Hospital
Baptist Health Lexington
A Randomized, Controlled, Open-label, Global Phase 3 Study Comparing the Efficacy of the Anti-PD-1 Antibody Tislelizumab (BGB-A317) Versus Chemotherapy as Second Line Treatment in Patients With Advanced Unresectable/Metastatic Esophageal Squamous Cell Carcinoma No dispute reported 06/30/2026 1190325038
Principal investigator 1 BeiGene, Ltd. $4,710.00 05/09/2025 Covered Recipient Teaching Hospital
Baptist Health Lexington
A Randomized, Controlled, Open-label, Global Phase 3 Study Comparing the Efficacy of the Anti-PD-1 Antibody Tislelizumab (BGB-A317) Versus Chemotherapy as Second Line Treatment in Patients With Advanced Unresectable/Metastatic Esophageal Squamous Cell Carcinoma No dispute reported 06/30/2026 1190320702
Principal investigator 1 BeiGene, Ltd. $5,805.00 05/09/2025 Covered Recipient Teaching Hospital
Baptist Health Lexington
A Randomized, Controlled, Open-label, Global Phase 3 Study Comparing the Efficacy of the Anti-PD-1 Antibody Tislelizumab (BGB-A317) Versus Chemotherapy as Second Line Treatment in Patients With Advanced Unresectable/Metastatic Esophageal Squamous Cell Carcinoma No dispute reported 06/30/2026 1190320722
Principal investigator 1 BeiGene, Ltd. $2,730.00 05/09/2025 Covered Recipient Teaching Hospital
Baptist Health Lexington
A Randomized, Controlled, Open-label, Global Phase 3 Study Comparing the Efficacy of the Anti-PD-1 Antibody Tislelizumab (BGB-A317) Versus Chemotherapy as Second Line Treatment in Patients With Advanced Unresectable/Metastatic Esophageal Squamous Cell Carcinoma No dispute reported 06/30/2026 1190325036
Principal investigator 1 BeiGene, Ltd. $8,100.00 05/09/2025 Covered Recipient Teaching Hospital
Baptist Health Lexington
A Randomized, Controlled, Open-label, Global Phase 3 Study Comparing the Efficacy of the Anti-PD-1 Antibody Tislelizumab (BGB-A317) Versus Chemotherapy as Second Line Treatment in Patients With Advanced Unresectable/Metastatic Esophageal Squamous Cell Carcinoma No dispute reported 06/30/2026 1190325050
Principal investigator 1 BeiGene, Ltd. $3,114.00 05/09/2025 Covered Recipient Teaching Hospital
Baptist Health Lexington
A Randomized, Controlled, Open-label, Global Phase 3 Study Comparing the Efficacy of the Anti-PD-1 Antibody Tislelizumab (BGB-A317) Versus Chemotherapy as Second Line Treatment in Patients With Advanced Unresectable/Metastatic Esophageal Squamous Cell Carcinoma No dispute reported 06/30/2026 1190325054
Principal investigator 1 GlaxoSmithKline, LLC. $2,800.00 04/28/2025 Non-covered Recipient Entity
BAPTIST HEALTHCARE SYSTEM INC
A RANDOMIZED, MULTICENTER, DOUBLE-BLIND, PHASE 3 STUDY TO INVESTIGATE No dispute reported 06/30/2026 1192150330
Principal investigator 1 GlaxoSmithKline, LLC. $6,160.00 04/28/2025 Non-covered Recipient Entity
BAPTIST HEALTHCARE SYSTEM INC
A RANDOMIZED, MULTICENTER, DOUBLE-BLIND, PHASE 3 STUDY TO INVESTIGATE No dispute reported 06/30/2026 1192150342
Principal investigator 1 GlaxoSmithKline, LLC. $18,200.00 04/28/2025 Non-covered Recipient Entity
BAPTIST HEALTHCARE SYSTEM INC
A RANDOMIZED, MULTICENTER, DOUBLE-BLIND, PHASE 3 STUDY TO INVESTIGATE No dispute reported 06/30/2026 1192154250
Principal investigator 1 ABBVIE INC. $7,400.00 04/24/2025 Covered Recipient Teaching Hospital
BAPTIST HEALTH LEXINGTON
A Study to Assess Disease Activity and Adverse Events of Intravenous (IV) Telisotuzumab Vedotin Compared to IV Docetaxel in Adult Participants With Previously Treated Non-Squamous Non-Small Cell Lung Cancer (NSCLC) No dispute reported 06/30/2026 1202406055
Principal investigator 1 ABBVIE INC. $3,120.00 04/24/2025 Covered Recipient Teaching Hospital
BAPTIST HEALTH LEXINGTON
A Study to Assess Disease Activity and Adverse Events of Intravenous (IV) Telisotuzumab Vedotin Compared to IV Docetaxel in Adult Participants With Previously Treated Non-Squamous Non-Small Cell Lung Cancer (NSCLC) No dispute reported 06/30/2026 1202406059
Principal investigator 1 Merck Sharp & Dohme LLC $2,500.00 04/16/2025 Covered Recipient Teaching Hospital
Baptist Health Lexington
A Randomized, Phase 3, Open-label Study to Investigate the Pharmacokinetics and Safety of Subcutaneous Pembrolizumab versus Intravenous Pembrolizumab, Administered with Platinum Doublet Chemotherapy, in the First-Line Treatment of Participants with Metast No dispute reported 06/30/2026 1232927565
Recipient GlaxoSmithKline, LLC. $67.84 04/15/2025 Covered Recipient Physician A RANDOMIZED, MULTICENTER, DOUBLE-BLIND, PHASE 3 STUDY TO INVESTIGATE No dispute reported 06/30/2026 1192159741
Recipient GlaxoSmithKline, LLC. $18.44 04/15/2025 Covered Recipient Physician A RANDOMIZED, MULTICENTER, DOUBLE-BLIND, PHASE 3 STUDY TO INVESTIGATE No dispute reported 06/30/2026 1192159745
Recipient GlaxoSmithKline, LLC. $29.59 04/15/2025 Covered Recipient Physician A RANDOMIZED, MULTICENTER, DOUBLE-BLIND, PHASE 3 STUDY TO INVESTIGATE No dispute reported 06/30/2026 1192159771
Principal investigator 1 Eli Lilly and Company $1,751.54 03/25/2025 Non-covered Recipient Entity
BAPTIST HEALTH MEDICAL GROUP INC
A PHASE 3, MULTICENTER, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY ASSESSING THE EFFICACY AND SAFETY OF OLOMORASIB IN COMBINATION WITH STANDARD OF CARE IMMUNOTHERAPY IN PARTICIPANTS WITH RESECTED OR UNRESECTABLE KRAS G12C-MUTANT, NON-SMALL CELL LUNG CANCER - SUNRAY-02 No dispute reported 06/30/2026 1187880883
Recipient GlaxoSmithKline, LLC. $3,833.21 03/14/2025 Covered Recipient Physician A RANDOMIZED, MULTICENTER, DOUBLE-BLIND, PHASE 3 STUDY TO INVESTIGATE No dispute reported 06/30/2026 1192154255
Recipient GlaxoSmithKline, LLC. $45.72 03/14/2025 Covered Recipient Physician A RANDOMIZED, MULTICENTER, DOUBLE-BLIND, PHASE 3 STUDY TO INVESTIGATE No dispute reported 06/30/2026 1192154258
Recipient GlaxoSmithKline, LLC. $36.42 03/14/2025 Covered Recipient Physician A RANDOMIZED, MULTICENTER, DOUBLE-BLIND, PHASE 3 STUDY TO INVESTIGATE No dispute reported 06/30/2026 1192159749
Recipient GlaxoSmithKline, LLC. $37.82 03/14/2025 Covered Recipient Physician A RANDOMIZED, MULTICENTER, DOUBLE-BLIND, PHASE 3 STUDY TO INVESTIGATE No dispute reported 06/30/2026 1192159754
Recipient GlaxoSmithKline, LLC. $616.84 03/14/2025 Covered Recipient Physician A RANDOMIZED, MULTICENTER, DOUBLE-BLIND, PHASE 3 STUDY TO INVESTIGATE No dispute reported 06/30/2026 1192159759
Recipient GlaxoSmithKline, LLC. $12.57 03/14/2025 Covered Recipient Physician A RANDOMIZED, MULTICENTER, DOUBLE-BLIND, PHASE 3 STUDY TO INVESTIGATE No dispute reported 06/30/2026 1192159763
Recipient GlaxoSmithKline, LLC. $21.47 03/14/2025 Covered Recipient Physician A RANDOMIZED, MULTICENTER, DOUBLE-BLIND, PHASE 3 STUDY TO INVESTIGATE No dispute reported 06/30/2026 1192159767
Recipient GlaxoSmithKline, LLC. $11.02 03/14/2025 Covered Recipient Physician A RANDOMIZED, MULTICENTER, DOUBLE-BLIND, PHASE 3 STUDY TO INVESTIGATE No dispute reported 06/30/2026 1192159776
Principal investigator 1 Novocure GmbH $23,128.00 03/12/2025 Covered Recipient Teaching Hospital
Baptist Health Lexington
EF-36 a pilot, randomized, open-label study evaluating the safety and effectiveness of Tumor Treating Fields (TTFields) with pembrolizumab for first-line treatment of advanced or metastatic non-small cell lung cancer (NSCLC). No dispute reported 06/30/2026 1250868004
Principal investigator 1 Daiichi Sankyo Inc. $54.75 02/11/2025 Covered Recipient Teaching Hospital
Baptist Health Lexington
DS7300-188 No dispute reported 06/30/2026 1223344039
Principal investigator 1 Daiichi Sankyo Inc. $31.00 02/11/2025 Covered Recipient Teaching Hospital
Baptist Health Lexington
DS7300-188 No dispute reported 06/30/2026 1223344041
Principal investigator 1 Daiichi Sankyo Inc. $31.00 02/11/2025 Covered Recipient Teaching Hospital
Baptist Health Lexington
DS7300-188 No dispute reported 06/30/2026 1223344043
Principal investigator 1 Daiichi Sankyo Inc. $31.00 02/11/2025 Covered Recipient Teaching Hospital
Baptist Health Lexington
DS7300-188 No dispute reported 06/30/2026 1223344045
Principal investigator 1 Daiichi Sankyo Inc. $31.00 02/11/2025 Covered Recipient Teaching Hospital
Baptist Health Lexington
DS7300-188 No dispute reported 06/30/2026 1223344047
Principal investigator 1 Daiichi Sankyo Inc. $31.00 02/11/2025 Covered Recipient Teaching Hospital
Baptist Health Lexington
DS7300-188 No dispute reported 06/30/2026 1223344049
Principal investigator 1 Daiichi Sankyo Inc. $17.60 02/11/2025 Covered Recipient Teaching Hospital
Baptist Health Lexington
DS7300-188 No dispute reported 06/30/2026 1223344055
Principal investigator 1 Daiichi Sankyo Inc. $15.50 02/11/2025 Covered Recipient Teaching Hospital
Baptist Health Lexington
DS7300-188 No dispute reported 06/30/2026 1223344073
Principal investigator 1 Daiichi Sankyo Inc. $15.50 02/11/2025 Covered Recipient Teaching Hospital
Baptist Health Lexington
DS7300-188 No dispute reported 06/30/2026 1223344077
Principal investigator 1 Daiichi Sankyo Inc. $31.00 02/11/2025 Covered Recipient Teaching Hospital
Baptist Health Lexington
DS7300-188 No dispute reported 06/30/2026 1223344079
Principal investigator 1 AstraZeneca Pharmaceuticals LP $91,051.37 01/29/2025 Covered Recipient Teaching Hospital
Baptist Health Lexington
A Phase III, Double-blind, Placebo-controlled, Multi-center International Study of Neoadjuvant/adjuvant Durvalumab for the Treatment of Patients with Resectable Stages II and III Non-small Cell Lung Cancer No dispute reported 06/30/2026 1185545445
Principal investigator 3 AstraZeneca Pharmaceuticals LP $29,663.57 01/22/2025 Covered Recipient Teaching Hospital
Baptist Health Lexington
A Phase III, double-blind, placebo-controlled, Randomized, Multicenter, International Study of Durvalumab Plus Oleclumab and Durvalumab Plus Monalizumab in Patients With Locally Advanced Stage III, Unresectable Non-small Cell Lung Cancer NSCLC No dispute reported 06/30/2026 1185545447
Principal investigator 1 Daiichi Sankyo Inc. $154.65 01/10/2025 Covered Recipient Teaching Hospital
Baptist Health Lexington
DS7300-188 No dispute reported 06/30/2026 1223344033
Principal investigator 1 Daiichi Sankyo Inc. $75.00 01/10/2025 Covered Recipient Teaching Hospital
Baptist Health Lexington
DS7300-188 No dispute reported 06/30/2026 1223344035
Principal investigator 1 Daiichi Sankyo Inc. $44.70 01/10/2025 Covered Recipient Teaching Hospital
Baptist Health Lexington
DS7300-188 No dispute reported 06/30/2026 1223344037
Principal investigator 1 Daiichi Sankyo Inc. $8.80 01/10/2025 Covered Recipient Teaching Hospital
Baptist Health Lexington
DS7300-188 No dispute reported 06/30/2026 1223344051
Principal investigator 1 Daiichi Sankyo Inc. $4.25 01/10/2025 Covered Recipient Teaching Hospital
Baptist Health Lexington
DS7300-188 No dispute reported 06/30/2026 1223344053
Principal investigator 1 Daiichi Sankyo Inc. $29.25 01/10/2025 Covered Recipient Teaching Hospital
Baptist Health Lexington
DS7300-188 No dispute reported 06/30/2026 1223344057
Principal investigator 1 Daiichi Sankyo Inc. $50.15 01/10/2025 Covered Recipient Teaching Hospital
Baptist Health Lexington
DS7300-188 No dispute reported 06/30/2026 1223344059
Principal investigator 1 Daiichi Sankyo Inc. $15.50 01/10/2025 Covered Recipient Teaching Hospital
Baptist Health Lexington
DS7300-188 No dispute reported 06/30/2026 1223344061
Principal investigator 1 Daiichi Sankyo Inc. $15.50 01/10/2025 Covered Recipient Teaching Hospital
Baptist Health Lexington
DS7300-188 No dispute reported 06/30/2026 1223344063
Principal investigator 1 Daiichi Sankyo Inc. $15.50 01/10/2025 Covered Recipient Teaching Hospital
Baptist Health Lexington
DS7300-188 No dispute reported 06/30/2026 1223344065
Principal investigator 1 Daiichi Sankyo Inc. $15.50 01/10/2025 Covered Recipient Teaching Hospital
Baptist Health Lexington
DS7300-188 No dispute reported 06/30/2026 1223344067
Principal investigator 1 Daiichi Sankyo Inc. $15.50 01/10/2025 Covered Recipient Teaching Hospital
Baptist Health Lexington
DS7300-188 No dispute reported 06/30/2026 1223344069
Principal investigator 1 Daiichi Sankyo Inc. $86.30 01/10/2025 Covered Recipient Teaching Hospital
Baptist Health Lexington
DS7300-188 No dispute reported 06/30/2026 1223344071
Principal investigator 1 Daiichi Sankyo Inc. $15.50 01/10/2025 Covered Recipient Teaching Hospital
Baptist Health Lexington
DS7300-188 No dispute reported 06/30/2026 1223344075